Márquez-Rodas, I. http://orcid.org/0000-0002-2476-668X
Arance, A.
Berrocal, A.
Larios, C. L.
Curto-García, J.
Campos-Tapias, I. X.
Blanca, A. B.
Martin-Algarra, S.
Article History
Received: 3 May 2019
Accepted: 9 August 2019
First Online: 21 August 2019
Compliance with ethical standards
:
: Iván Márquez Rodas has participated in consulting and advisory boards of BMS, MSD, Novartis, Roche, Pierre-Fabre, Amgen, AstraZeneca, Merck-Serono, Incyte, Bioncotech, and Sanofi. Ana Arance has participated in consulting, advisory boards and Speaker’s bureau of BMS, Roche, MSD and Novartis. Alfonso Berrocal has received honoraria for consulting and advisory boards of MSD, BMS, Roche and Novartis. Cindy L. Larios and Jordi Curto are employed by MFAR Clinical Research, a CRO for Amgen for this study, analysis and manuscript. Ignasi X. Campos Tapias and Ana Belén Blanca are full-time employees at Amgen S.A. and own Amgen stocks. Salvador Martín Algarra reports receiving advisory board fees from Amgen, BMS, Incyte, Merck-Serono, MSD, Pierre-Fabre, Tesaro and Roche; speaker activities fees from BMS, MSD and Pierre-Fabre; consulting fees from Novartis and travel support from Roche.
: The study was approved by an independent Ethical Committee and conducted in accordance with the good clinical practice (GCP), the principles of the Declaration of Helsinki and current local applicable regulations.
: All patients participating in the study signed informed consent.